Comirnaty Original & Omicron BA.4/BA.5 (COVID-19 mRNA vaccine, Bivalent (Original and Omicron BA.4/BA.5) is indicated as a booster dose

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

October 14, 2022

Comirnaty Original & Omicron BA.4/BA.5 (COVID-19 mRNA vaccine, Bivalent (Original and Omicron BA.4/BA.5) is indicated as a booster dose for active immunization against COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

The safety and effectiveness of a booster dose of Comirnaty Original & Omicron BA.4/BA.5 for individuals 12 years of age and older is inferred from studies of a booster dose of Comirnaty Original/Omicron BA.1 in individuals >55 years of age and also data from studies of a booster dose of monovalent Omicron BA.1 in individuals 18 to ≤55 years of age.

This bivalent vaccine is available in vials with gray cap and gray label border. Please review the label carefully to ensure that you select the appropriate vaccine for immunization.

Please review the Comirnaty Original & Omicron BA.4/BA.5, Bivalent Product Monograph for more complete information. Each Product Monograph is available below, at www.pfizer.ca/products, or www.cvdvaccine.ca